Harnessing Artificial Intelligence to Improve Oncology Care

Oncology professionals must stay current with evolving artificial intelligence (AI) technologies to effectively interpret their outputs, integrate them into clinical decision-making, and anticipate future developments. This session is designed to  meet the educational need of clinicians for foundational knowledge of AI applications and trends that will enhance patient care, improve outcomes, and support precision medicine approaches.

Target Audience

This program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to: 

  • Review current applications of artificial intelligence (AI) tools across the oncology care continuum.
  • Describe emerging technologies and how they may  support more precise, efficient, and patient-centered cancer care in the near future.
Additional information
Supporters: 

This educational activity is supported by educational grants from: AstraZeneca; Exact Sciences; Johnson & Johnson; Novartis; PharmaEssentia; Puma Biotechnology; Recordati Rare Disease Inc.; Revolution Medicines; Sirtex; Taiho Oncology, Inc.

This educational activity is supported by independent medical educational grants from: AbbVie; ADC Therapeutics; GSK

Supported by independent educational grants from: Blue Earth Diagnostics; Daiichi Sankyo; Merck & Co., Inc., Rahway, NJ, USA

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

This educational activity is supported by a medical education grant from Exelixis, Inc.

This project has been made possible in part by a grant from Varian, a Siemens Healthineers company. 

Course summary
Available credit: 
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
06/15/2026
Course expires: 
03/01/2027
Part of: 
Recorded Presentations from the NCCN 2026 Annual Conference
Moderator
 
Penelope Fu, MD, MPH
City of Hope National Medical Center
 
Presenter
 
Travis Osterman, DO, MS
Vanderbilt-Ingram Cancer Center
 
NCCN Continuing Education Disclosure Policy
 
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
 
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 
 
Definitions  
 
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 
 
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
 
Faculty Disclaimers  
 
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery. Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
 
Faculty Disclosures
 
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Penelope Fu, MD, MPH
 
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated. 
 
Travis Osterman, DO, MS
AstraZeneca Pharmaceuticals LP: Consulting Fee; Scientific Advisor
Biodesix Inc.: Consulting Fee; Scientific Advisor
COTA Healthcare: Consulting Fee; Scientific Advisor
eHealth Technologies: Consulting Fee; Scientific Advisor
Flagship Biosciences, Inc.: Consulting Fee; Scientific Advisor
GE Healthcare: Grant/Research Support
GenomOncology LLC: Consulting Fee; Scientific Advisor
IBM: Grant/Research Support
Microsoft: Grant/Research Support
Outcomes Insights, Inc.: Consulting Fee; Scientific Advisor
Tempus AI: Scientific Advisor
 
NCCN Staff Disclosures
 
The planners listed below have the following relevant relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
 
Crystal S. Denlinger, MD
AbbVie, Inc.: Grant/Research Support
Bluebird bio: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Genentech, Inc.: Grant/Research Support
GSK: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Sanofi: Grant/Research Support
 
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 
image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-26-060-H01-P
 
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until March 1, 2027. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: 

  • A device with an Internet connection and sound playback capability (speakers or a headset) 
  • Adobe Reader or other PDF reader software for certificate viewing/printing